NEW YORK, June 8, 2011 /PRNewswire/ -- According to a report published today by Thomson CompuMark, part of Thomson Reuters, the pharmaceutical industry has begun to adapt to stricter governmental brand name standards globally by rapidly increasing the number of trademarks it files for every new drug. These newer standards by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) are part of an effort to prevent look-alike/sound-alike pharmaceutical brand names and have led to increased rejection rates of new drug names.
The special report, Pharmaceutical Trademarks: How to Survive the Name Game – New Challenges and Opportunities for Pharmaceutical Companies, tracks trends in pharmaceutical trademark activity over the last 30 years, incorporates input from leading trademark attorneys and pharmaceutical industry executives and analyzes trademark initiatives at the FDA and EMA to shed light on this critical issue. Following are some of the key observations in the analysis:
"Pharmaceutical companies are facing more hurdles than ever to get new drugs to market, but, in the long run, the steps they are taking now to adapt to the new regulatory reality will improve safety and efficiency in the marketplace," said Martin Burke, managing director of Thomson CompuMark. "The key to that transition will be giving stakeholders access to the information they need to make informed decisions. We will continue to help the process by developing analytics that help brand owners reduce risk by properly vetting new trademark names on a global basis."
This report was compiled using Thomson CompuMark data to identify trends in pharmaceutical trademark applications and top filers by company and country. Thomson CompuMark Pharma Search reports allow pharmaceutical brand owners and their legal teams to screen trademark names globally, across different sources to review critical information quickly and efficiently, identifying potentially troublesome naming constructs before they ever become a hindrance to the new drug approval process.
To view the full report, Pharmaceutical Trademarks: How to Survive the Name Game – New Challenges and Opportunities for Pharmaceutical Companies go to: http://compumark.thomson.com/do/pharma_special_report.
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 55,000 people and operates in over 100 countries. For more information, go to http://thomsonreuters.com.
|SOURCE Thomson Reuters|
Copyright©2010 PR Newswire.
All rights reserved